Compositions for affecting weight loss
AssigneeNalpropion Pharmaceuticals LLC
InventorsEckard Weber, Michael Alexander Cowley
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance α-MSH activity.
Claims17
A composition for affecting weight loss comprising a first compound and a second compound, wherein said first compound is an opioid antagonist selected from alvimopan, norbinaltorphimine, nalmefene, naloxone, methylnaltrexone, and nalorphine, and pharmaceutically acceptable salts thereof, and said second compound is selected from fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, sibutramine, duloxetine, and venlafaxine, and pharmaceutically acceptable salts thereof.
A composition comprising:
- a first compound selected from nalmefene, or naloxone, or pharmaceutically acceptable salts thereof;
- and
- a second compound selected from fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, sibutramine, duloxetine, and venlafaxine, and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.